HWK-016 / Whitehawk Therapeutics, Hangzhou DAC Biotech, WuXi AppTec - LARVOL DELTA

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio… (PRNewswire) - "Aadi Bioscience...announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics...and HANGZHOU DAC....Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales."

Licensing / partnership • Solid Tumor